Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tislelizumab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04834986
What this trial is testing

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Who this might be right for
Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05611879
What this trial is testing

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Who this might be right for
NSCLC, Stage III
Beijing Tsinghua Chang Gung Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05160727
What this trial is testing

Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer

Who this might be right for
Mismatch Repair-proficientColorectal Cancer MetastaticMicrosatellite Stable
Zhejiang Cancer Hospital 44
Testing effectiveness (Phase 2)Study completedNCT04952597
What this trial is testing

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Who this might be right for
Limited Stage Small Cell Lung Cancer
BeiGene 126
Testing effectiveness (Phase 2)Active Not RecruitingNCT04734262
What this trial is testing

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Metastatic Breast Cancer
Fudan University 98
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07655661
What this trial is testing

Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Ming Liu 52
Testing effectiveness (Phase 2)UnknownNCT05485883
What this trial is testing

Tislelizumab Plus Lenvatinib in Stage III-IV RCC

Who this might be right for
Advanced Kidney Cancer
Tianjin Medical University Second Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05343325
What this trial is testing

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Who this might be right for
Head and Neck Squamous Cell CarcinomaNeoadjuvant Treatment
Fifth Affiliated Hospital, Sun Yat-Sen University 25
Large-scale testing (Phase 3)Looking for participantsNCT06383780
What this trial is testing

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Who this might be right for
Nasopharyngeal Carcinoma
XIANG YANQUN 90
Not applicableEnrolling By InvitationNCT07450040
What this trial is testing

Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma

Who this might be right for
ORROSPFS
Eye & ENT Hospital of Fudan University 60
Testing effectiveness (Phase 2)Looking for participantsNCT05954897
What this trial is testing

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Guangdong Provincial People's Hospital 29
Large-scale testing (Phase 3)Ended earlyNCT04486391
What this trial is testing

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
BeiGene 3
Testing effectiveness (Phase 2)Study completedNCT05116085
What this trial is testing

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Who this might be right for
Colorectal Cancer
BeiGene 33
Large-scale testing (Phase 3)Not Yet RecruitingNCT07132008
What this trial is testing

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

Who this might be right for
Colonic NeoplasmsNeoadjuvant TherapyImmune Checkpoint Inhibitors
First Affiliated Hospital of Guangxi Medical University 94
Testing effectiveness (Phase 2)Study completedNCT03209973
What this trial is testing

Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
BeiGene 70
Testing effectiveness (Phase 2)Looking for participantsNCT07086456
What this trial is testing

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Who this might be right for
SurufatinibTislelizumabConcurrent Chemoradiotherapy+2 more
Sun Yat-sen University 80
Large-scale testing (Phase 3)Looking for participantsNCT06332274
What this trial is testing

TislelizUMaB in canceR Patients With molEcuLar residuaL Disease

Who this might be right for
CancerLung CancerColo-rectal Cancer+2 more
Gustave Roussy, Cancer Campus, Grand Paris 717
Testing effectiveness (Phase 2)UnknownNCT05545124
What this trial is testing

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Who this might be right for
Hepatocellular Carcinoma
Henan Cancer Hospital 32
Testing effectiveness (Phase 2)Looking for participantsNCT07418190
What this trial is testing

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Who this might be right for
Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University 33
Testing effectiveness (Phase 2)UnknownNCT05394415
What this trial is testing

Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC

Who this might be right for
Esophageal Squamous Cell CarcinomaTislelizumabChemoradiation
Jiangsu Cancer Institute & Hospital 30
Next Page